VISTA Inhibitors in Cancer Immunotherapy: a Short Perspective on Recent Progresses

Overview

Journal RSC Med Chem

Publisher Royal Society of Chemistry

Specialty Chemistry

Date 2021 Nov 15

PMID 34778768

Citations 10

Authors

Chenyang Wu

Xin Cao

Xiaojin Zhang

Affiliations

Soon will be listed here.

Abstract

V-domain immunoglobulin (Ig) suppressor of T cell activation (VISTA) is a novel negative checkpoint regulator that mediates T cell proliferation and cytokine production. The VISTA signaling pathway blockade has been proved as a promising strategy for cancer immunotherapy. Recent VISTA sequence analysis and crystal structure investigations have revealed its independent and unique function as compared with B7 family members, such as PD-1. This review will discuss VISTA binding partners and compare the structural differences between VISTA and other B7 family members, focusing on VISTA functions in immune activation and maintaining T cell quiescence. Recent progress and the therapeutic potential of biomacromolecules, such as monoclonal antibodies (mAbs) and small molecules targeting VISTA, are also discussed. Among these, a first-in-class small-molecule antagonist, , is highlighted.

Citing Articles

Current Advances in Immunotherapy Management of Esophageal Cancer.

Pyreddy S, Kim S, Miyamoto W, Talib Z, GnanaDev D, Rahnemai-Azar A Cancers (Basel). 2025; 17(5).

PMID: 40075698 PMC: 11898678. DOI: 10.3390/cancers17050851.

Structural insights into antibody-based immunotherapy for hepatocellular carcinoma.

Shah M, Hussain M, Woo H Genomics Inform. 2025; 23(1):1.

PMID: 39833954 PMC: 11744992. DOI: 10.1186/s44342-024-00033-0.

Myocarditis Induced by Immune Checkpoint Inhibitors: An Exploratory Review.

Zavaleta-Monestel E, Garcia-Montero J, Anchia-Alfaro A, Rojas-Chinchilla C, Quesada-Villasenor R, Arguedas-Chacon S Cureus. 2024; 16(8):e67314.

PMID: 39301338 PMC: 11412606. DOI: 10.7759/cureus.67314.

Nanoparticles targeting immune checkpoint protein VISTA induce potent antitumor immunity.

Moon T, Ta H, Bhalotia A, Paulsen K, Hutchinson D, Arkema G J Immunother Cancer. 2024; 12(8).

PMID: 39209454 PMC: 11367342. DOI: 10.1136/jitc-2024-008977.

Macrophage Perspectives in Liver Diseases: Programmed Death, Related Biomarkers, and Targeted Therapy.

Qian Z, Xiong W, Mao X, Li J Biomolecules. 2024; 14(6).

PMID: 38927103 PMC: 11202214. DOI: 10.3390/biom14060700.

References

ElTanbouly M, Croteau W, Noelle R, Lines J . VISTA: a novel immunotherapy target for normalizing innate and adaptive immunity. Semin Immunol. 2019; 42:101308. PMC: 7233310. DOI: 10.1016/j.smim.2019.101308. View

Villarroel-Espindola F, Yu X, Datar I, Mani N, Sanmamed M, Velcheti V . Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer. Clin Cancer Res. 2017; 24(7):1562-1573. PMC: 5884702. DOI: 10.1158/1078-0432.CCR-17-2542. View

Cao X, Ren X, Zhou Y, Mao F, Lin Y, Wu H . VISTA Expression on Immune Cells Correlates With Favorable Prognosis in Patients With Triple-Negative Breast Cancer. Front Oncol. 2021; 10:583966. PMC: 7829913. DOI: 10.3389/fonc.2020.583966. View

Gabr M, Gambhir S . Discovery and Optimization of Small-Molecule Ligands for V-Domain Ig Suppressor of T-Cell Activation (VISTA). J Am Chem Soc. 2020; 142(38):16194-16198. DOI: 10.1021/jacs.0c07276. View

Wang J, Wu G, Manick B, Hernandez V, Renelt M, Erickson C . VSIG-3 as a ligand of VISTA inhibits human T-cell function. Immunology. 2018; 156(1):74-85. PMC: 6283650. DOI: 10.1111/imm.13001. View

Flies D, Wang S, Xu H, Chen L . Cutting edge: A monoclonal antibody specific for the programmed death-1 homolog prevents graft-versus-host disease in mouse models. J Immunol. 2011; 187(4):1537-41. PMC: 3150865. DOI: 10.4049/jimmunol.1100660. View

Yoon K, Byun S, Kwon E, Hwang S, Chu K, Hiraki M . Control of signaling-mediated clearance of apoptotic cells by the tumor suppressor p53. Science. 2015; 349(6247):1261669. PMC: 5215039. DOI: 10.1126/science.1261669. View

Sasikumar P, Ramachandra R, Adurthi S, Dhudashiya A, Vadlamani S, Vemula K . A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy. Mol Cancer Ther. 2019; 18(6):1081-1091. DOI: 10.1158/1535-7163.MCT-18-0737. View

Hu X, Qie C, Jiang J, Xie X, Chen W, Liu W . M351-0056 is a novel low MW compound modulating the actions of the immune-checkpoint protein VISTA. Br J Pharmacol. 2021; 178(6):1445-1458. PMC: 9328666. DOI: 10.1111/bph.15357. View

10.

Seo W, Lee C, Jung S, Lee D, Park H, Jeong D . Expression of VISTA on tumor-infiltrating immune cells correlated with short intravesical recurrence in non-muscle-invasive bladder cancer. Cancer Immunol Immunother. 2021; 70(11):3113-3122. PMC: 10992450. DOI: 10.1007/s00262-021-02906-7. View

11.

Zong L, Zhou Y, Zhang M, Chen J, Xiang Y . VISTA expression is associated with a favorable prognosis in patients with high-grade serous ovarian cancer. Cancer Immunol Immunother. 2019; 69(1):33-42. PMC: 6949319. DOI: 10.1007/s00262-019-02434-5. View

12.

Irurzun-Arana I, McDonald T, Troconiz I, Michor F . Pharmacokinetic Profiles Determine Optimal Combination Treatment Schedules in Computational Models of Drug Resistance. Cancer Res. 2020; 80(16):3372-3382. PMC: 7442591. DOI: 10.1158/0008-5472.CAN-20-0056. View

13.

He H, Gao Y, Fu J, Zhou Q, Wang X, Bai B . VISTA and PD-L1 synergistically predict poor prognosis in patients with extranodal natural killer/T-cell lymphoma. Oncoimmunology. 2021; 10(1):1907059. PMC: 8032243. DOI: 10.1080/2162402X.2021.1907059. View

14.

Mehta N, Maddineni S, Kelly R, Lee R, Hunter S, Silberstein J . An engineered antibody binds a distinct epitope and is a potent inhibitor of murine and human VISTA. Sci Rep. 2020; 10(1):15171. PMC: 7494997. DOI: 10.1038/s41598-020-71519-4. View

15.

Blando J, Sharma A, Higa M, Zhao H, Vence L, Yadav S . Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proc Natl Acad Sci U S A. 2019; 116(5):1692-1697. PMC: 6358697. DOI: 10.1073/pnas.1811067116. View

16.

Blevins D, Hanley R, Bolduc T, Powell D, Gignac M, Walker K . Assessment of Putative PD-1/PD-L1 Inhibitors: Suggestions of an Alternative Mode of Action. ACS Med Chem Lett. 2019; 10(8):1187-1192. PMC: 6691557. DOI: 10.1021/acsmedchemlett.9b00221. View

17.

ElTanbouly M, Schaafsma E, Noelle R, Lines J . VISTA: Coming of age as a multi-lineage immune checkpoint. Clin Exp Immunol. 2020; 200(2):120-130. PMC: 7160665. DOI: 10.1111/cei.13415. View

18.

Xie X, Chen C, Chen W, Jiang J, Wang L, Li T . Structural Basis of VSIG3: The Ligand for VISTA. Front Immunol. 2021; 12:625808. PMC: 8027081. DOI: 10.3389/fimmu.2021.625808. View

19.

Choi J, Kim Y, Yun K, Won C, Lee M, Choi J . The prognostic significance of VISTA and CD33-positive myeloid cells in cutaneous melanoma and their relationship with PD-1 expression. Sci Rep. 2020; 10(1):14372. PMC: 7462859. DOI: 10.1038/s41598-020-71216-2. View

20.

Sasikumar P, Sudarshan N, Adurthi S, Ramachandra R, Samiulla D, Lakshminarasimhan A . PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy. Commun Biol. 2021; 4(1):699. PMC: 8187357. DOI: 10.1038/s42003-021-02191-1. View